These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 23973432

  • 1. Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor.
    Hammer LA, Zagon IS, McLaughlin PJ.
    Brain Res Bull; 2013 Sep; 98():122-31. PubMed ID: 23973432
    [Abstract] [Full Text] [Related]

  • 2. Improved clinical behavior of established relapsing-remitting experimental autoimmune encephalomyelitis following treatment with endogenous opioids: implications for the treatment of multiple sclerosis.
    Hammer LA, Zagon IS, McLaughlin PJ.
    Brain Res Bull; 2015 Mar; 112():42-51. PubMed ID: 25647234
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis.
    McLaughlin PJ, McHugh DP, Magister MJ, Zagon IS.
    BMC Immunol; 2015 Apr 24; 16():24. PubMed ID: 25906771
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
    Rahn KA, McLaughlin PJ, Zagon IS.
    Brain Res; 2011 Mar 24; 1381():243-53. PubMed ID: 21256121
    [Abstract] [Full Text] [Related]

  • 10. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ.
    Immunobiology; 2011 May 24; 216(5):579-90. PubMed ID: 20965606
    [Abstract] [Full Text] [Related]

  • 11. Elevated serum [Met5]-enkephalin levels correlate with improved clinical and behavioral outcomes in experimental autoimmune encephalomyelitis.
    Ludwig MD, Zagon IS, McLaughlin PJ.
    Brain Res Bull; 2017 Sep 24; 134():1-9. PubMed ID: 28647454
    [Abstract] [Full Text] [Related]

  • 12. T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6 x SJL) F1 mice.
    Zhang GX, Yu S, Gran B, Li J, Calida D, Ventura E, Chen X, Rostami A.
    J Neuroimmunol; 2004 Mar 24; 148(1-2):1-10. PubMed ID: 14975581
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis.
    Whitham RH, Bourdette DN, Hashim GA, Herndon RM, Ilg RC, Vandenbark AA, Offner H.
    J Immunol; 1991 Jan 01; 146(1):101-7. PubMed ID: 1701788
    [Abstract] [Full Text] [Related]

  • 16. Relapsing and remitting experimental allergic encephalomyelitis: a focused response to the encephalitogenic peptide rather than epitope spread.
    Takács K, Chandler P, Altmann DM.
    Eur J Immunol; 1997 Nov 01; 27(11):2927-34. PubMed ID: 9394820
    [Abstract] [Full Text] [Related]

  • 17. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
    Ingwersen J, Wingerath B, Graf J, Lepka K, Hofrichter M, Schröter F, Wedekind F, Bauer A, Schrader J, Hartung HP, Prozorovski T, Aktas O.
    J Neuroinflammation; 2016 Feb 26; 13():48. PubMed ID: 26920550
    [Abstract] [Full Text] [Related]

  • 18. Protective Effects on Central Nervous System by Acidic Polysaccharide of Panax ginseng in Relapse-Remitting Experimental Autoimmune Encephalomyelitis-Induced SJL/J Mice.
    Bing SJ, Ha D, Hwang I, Park E, Ahn G, Song JY, Jee Y.
    Am J Chin Med; 2016 Feb 26; 44(6):1099-1110. PubMed ID: 27627913
    [Abstract] [Full Text] [Related]

  • 19. Timing of treatment with an endogenous opioid alters immune response and spinal cord pathology in female mice with experimental autoimmune encephalomyelitis.
    Patel C, Zagon IS, Pearce-Clawson M, McLaughlin PJ.
    J Neurosci Res; 2022 Feb 26; 100(2):551-563. PubMed ID: 34821408
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.